3-methyl-3,7-diazabicyclo[3.3.1]nonane | 58324-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-methyl-3,7-diazabicyclo[3.3.1]nonane
• 英文别名: 3-methylbispidine；3-methyl-3,7-diaza-bicyclo[3.3.1]nonane；N-Methylbispidin
• CAS: 58324-99-5
• 化学式: C₈H₁₆N₂
• mdl: MFCD18324773
• 分子量: 140.228
• InChiKey: CSRBWSGDNSONNP-UHFFFAOYSA-N

物化性质

• 沸点：
  200.6±8.0 °C(Predicted)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-3,7-diazabicyclo[3.3.1]nonane 在 四甲基乙二胺 、 仲丁基锂 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 环戊烷 为溶剂， 反应 20.0h， 生成 1-(2-endo-methyl-7-methyl-3,7-diazabicyclo[3.3.1]non-3-yl)-2-(S)-(6-methoxynaphthalen-2-yl)propan-1-one
  参考文献：
  名称：

  Is the A-Ring of Sparteine Essential for High Enantioselectivity in the Asymmetric Lithiation−Substitution of N-Boc-pyrrolidine?

  摘要：

  The simplest chiral portion of sparteine, N,N'-dimethyl-2-endo-methylbispidine, was prepared and evaluated in the asymmetric lithiation-substitution of N-Boc-pyrrolidine. The results indicate that the complete A-ring of sparteine is essential for high levels of asymmetric induction. DFT-QSSR analyses of the diamine/Li+ complexes and DFT calculations of the pertinent i-PrLi/diamine/N-Boc-pyrrolidine complexes are predictive and provide complementary pictures of the stereochemical features critical to this transformation.

  DOI：

  10.1021/ja046321i
• 作为产物：
  描述：

  3-苄基-7-甲基-3,7-二氮杂双环[3.3.1]-9-壬酮 在 palladium on activated charcoal 氢氧化钾 、 氢气 、 一水合肼 作用下， 以 溶剂黄146 、 二乙二醇 为溶剂， 反应 11.0h， 生成 3-methyl-3,7-diazabicyclo[3.3.1]nonane
  参考文献：
  名称：

  包含双吡啶骨架的手性氨基醇的合成及其作为配体在 CO 和 CC 基团的对映选择性催化加成中的应用

  摘要：

  已经开发了两种普遍适用的合成包含双吡啶骨架的手性氨基醇的路线。在线性路线 A 中，双吡啶骨架是由手性伯胺通过中间体形成哌啶酮和双吡啶酮依次构建的。在收敛路线 B ​​中，首先形成非手性双吡啶，然后通过氮碱与手性亲电试剂的反应引入 N-取代基。为了确定双吡啶核心及其 N 取代基是否能影响对映选择性转化的空间过程，研究了通过这两种途径构建的双吡啶氨基醇作为手性配体在二乙基锌对醛和查耳酮的对映选择性催化加成中。一般来说，含有一个手性氨基醇片段和没有立体中心的第二个氨基取代基的三齿配体比具有两个氨基醇结构单元的四齿配体更有效。使用最好的配体，二乙基锌对芳香族和脂肪族醛的对映选择性加成以 83-98% ee 进行，二乙基锌向查耳酮的镍催化加成达到 85% ee。

  DOI：

  10.1002/(sici)1099-0690(200002)2000:3<391::aid-ejoc391>3.0.co;2-r

文献信息

• Synthesis of Chiral Amino Alcohols Embodying the Bispidine Framework and Their Application as Ligands in Enantioselectively Catalyzed Additions to CO and CC Groups
  作者：Jan Spieler、Oliver Huttenloch、Herbert Waldmann

  DOI：10.1002/(sici)1099-0690(200002)2000:3<391::aid-ejoc391>3.0.co;2-r

  日期：2000.2

  course of enantioselective transformations, bispidine amino alcohols built up by these two routes were investigated as chiral ligands in the enantioselectively catalyzed addition of diethylzinc to aldehydes and chalcone. In general, tridentate ligands containing one chiral amino alcohol fragment and a second amino substituent without a stereogenic center were more efficient than tetradentate ligands with

  已经开发了两种普遍适用的合成包含双吡啶骨架的手性氨基醇的路线。在线性路线 A 中，双吡啶骨架是由手性伯胺通过中间体形成哌啶酮和双吡啶酮依次构建的。在收敛路线 B ​​中，首先形成非手性双吡啶，然后通过氮碱与手性亲电试剂的反应引入 N-取代基。为了确定双吡啶核心及其 N 取代基是否能影响对映选择性转化的空间过程，研究了通过这两种途径构建的双吡啶氨基醇作为手性配体在二乙基锌对醛和查耳酮的对映选择性催化加成中。一般来说，含有一个手性氨基醇片段和没有立体中心的第二个氨基取代基的三齿配体比具有两个氨基醇结构单元的四齿配体更有效。使用最好的配体，二乙基锌对芳香族和脂肪族醛的对映选择性加成以 83-98% ee 进行，二乙基锌向查耳酮的镍催化加成达到 85% ee。
• [EN] 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS<br/>[FR] CARBOXAMIDES DE 3,7-DIAZABICYCLO[3.3.1]NONANE À TITRE D'AGENTS ANTITHROMBOTIQUES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015044951A1

  公开（公告）日：2015-04-02

  The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

  本发明涉及3,7-二氮杂双环[3.3.1]壬烷羧酰胺及其制备方法。本发明还涉及具有抗血栓（抗血小板）活性的一般式（1）化合物。该发明还涉及将这些基团用作体外和体内介导的胶原受体抑制剂，抑制胶原诱导的血小板粘附和聚集。此外，该发明还涉及这类化合物通过双重机制表现出抗血小板功效，既抑制了胶原又抑制了U46619（血栓素受体激动剂）诱导的血小板聚集。一般式（1）中，其中，R'为；其中R选自烷基、酰基、对甲苯磺酰基、叔丁氧羰基、芳基烷基或取代芳基烷基；R''优选选自卤素、氰基、低烷基、芳基、取代芳基和对甲苯磺基；R1选自氢和低烷基；R2选自低烷基和芳基；R3选自叔丁氧羰基和苯甲氧羰基；n = 0,1。
• [EN] INHIBITORS OF RHO ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE<br/>[FR] INHIBITEURS DE PROTÉINE KINASE À SUPERENROULEMENT D'HÉLICES ALPHA (« COILED-COIL ») ASSOCIÉE À RHO
  申请人：KADMON CORP LLC

  公开号：WO2019045824A1

  公开（公告）日：2019-03-07

  The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.

  这项发明涉及ROCK1和/或ROCK2的抑制剂。还提供了抑制ROCK1和/或ROCK2的方法，这些方法对治疗疾病是有用的。
• [EN] HETEROCYCLIC COMPOUND ACTING AS KRAS G12D INHIBITOR<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE AGISSANT COMME INHIBITEUR DE KRAS G12D<br/>[ZH] 作为KRAS G12D抑制剂的杂环化合物
  申请人：HANGZHOU INNOGATE PHARMA CO LTD

  公开号：WO2022214102A1

  公开（公告）日：2022-10-13

  本发明提供了作为KRAS G12D抑制剂的化合物，具体地，本发明提供了一种如下式(I)所示结构的化合物，或其光学异构体，药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。所述的化合物可以用于治疗或预防与KRAS G12D的活性或表达量相关的疾病或病症。
• Guest/Host Relationships in the Synthesis of the Novel Cage-Based Zeolites SSZ-35, SSZ-36, and SSZ-39
  作者：Paul Wagner、Yumi Nakagawa、Greg S. Lee、Mark E. Davis、Saleh Elomari、Ronald C. Medrud、S. I. Zones

  DOI：10.1021/ja990722u

  日期：2000.1.1

  Here, we report the synthesis and structure of three high-silica molecular sieves, SSZ-35, SSZ-36, and SSZ-39, that are prepared from a library of 37 different cyclic and polycyclic quaternized amine molecules that are used as structure-directing agents (SDAs). The size and shape of the quaternized amine molecules are purposely designed in order to obtain novel zeolite structures, and the synthesis of these molecules is presented. The selectivity for the three molecular sieve phases is found to depend on both the SDA and the degree of heteroatom lattice substitution of Al3+ or B3+ in the silicate framework. Molecular modeling is utilized to probe the effects of the nonbonded SDA/zeolite-framework interaction energy on the selectivity for the observed molecular sieve phase. The Rietveld refinement of the powder X-ray data confirms the structure of the SSZ-39 zeolite to be isomorphous with the aluminophosphate molecular sieve, SAPO-LS (AEI). The structure of SSZ-36 is found to possess a range of fault probabilities between the two-dimensional channel system, end-member polymorphs, ITQ-3 and RUB-13 (International Zeolite Association Codes ITE and RTH, respectively). The SSZ-35 structure is reported to contain a one-dimensional pore system possessing stacked cages circumscribed by alternating rings of 10 and 18 tetrahedral atoms (10- and 18-membered rings).